MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

MDT

87.15

-1.56%↓

A

115.28

-0.44%↓

VEEV

150.98

-3.88%↓

HQY

79.35

-5.48%↓

TLRY

6.6

-3.51%↓

Search

Innoviva Inc

Ouvert

SecteurSoins de santé

23.82 -0.46

Résumé

Variation du prix de l'action

24h

Actuel

Min

23.8

Max

24.37

Chiffres clés

By Trading Economics

Revenu

152M

242M

Ventes

10M

118M

P/E

Moyenne du Secteur

6.976

66.418

Marge bénéficiaire

204.74

Employés

159

EBITDA

100M

208M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+56.65% upside

Dividendes

By Dow Jones

Prochains Résultats

5 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

58M

1.7B

Ouverture précédente

24.28

Clôture précédente

23.82

Sentiment de l'Actualité

By Acuity

46%

54%

154 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB: Higher Energy Prices to Raise Production, Consumer Costs

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB Projects Japan GDP Growth at 0.7% in 2026, 0.6% in 2027

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB Projects South Korea GDP Growth at 1.9% in 2026, 1.9% in 2027

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

Extent of Slowdown Hinges on Duration of MidEast Conflict, ADB Says

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB Projects India GDP Growth at 6.9% in 2026, 7.3% in 2027

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB Projects China GDP Growth at 4.6% in 2026, 4.5% in 2027

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB Pojects Australia GDP Grrowth at 2.0% in 2026, 2.9% in 2027

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

ADB Projects Taiwan GDP Growth at 7.6% in 2026, 4.0% in 2027

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

Geopolitical Risks Make Asia's Economic Outlook Highly Uncertain, ADB Says

10 avr. 2026, 00:00 UTC

Principaux Événements d'Actualité

Asia Regional Growth Likely to Moderate in 2026-2027, ADB Says

9 avr. 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

9 avr. 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Inflation Concerns -- Market Talk

9 avr. 2026, 23:14 UTC

Market Talk

Jefferies Upbeat on Australian Miners, But Recession a Key Risk -- Market Talk

9 avr. 2026, 23:14 UTC

Market Talk

Global Equities Roundup: Market Talk

9 avr. 2026, 23:07 UTC

Market Talk

Centaurus's Supply Deal with Glencore Supports Jaguar Development -- Market Talk

9 avr. 2026, 22:54 UTC

Market Talk

Transurban Lacks Appeal as Higher Fuel Prices Slow Traffic -- Market Talk

9 avr. 2026, 22:31 UTC

Principaux Événements d'Actualité

Trump on Truth Social: 'That Is Not the Agreement We Have!'

9 avr. 2026, 22:31 UTC

Principaux Événements d'Actualité

Trump on Truth Social: 'Iran Is Doing a Very Poor Job, Dishonorable Some Would Say, of Allowing Oil to Go Through the Strait of Hormuz'

9 avr. 2026, 20:57 UTC

Principaux Événements d'Actualité

U.S. Oil Prices Are Back Near $100 After Israel Keeps Up Air Strikes on Lebanon -- Barrons.com

9 avr. 2026, 20:55 UTC

Résultats

Stryker: Believes Incident Hasn't Had, and Isn't Reasonably Likely to Have, a Material Impact on 2026 Full-Year Guidance >SYK

9 avr. 2026, 20:55 UTC

Résultats

Stryker: Determined Incident Had Material Impact on Operations, With Resulting Impact on Financial Results for 1Q >SYK

9 avr. 2026, 20:55 UTC

Résultats

Stryker: Investigation of Cybersecurity Incident Remains Ongoing >SYK

9 avr. 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

9 avr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 avr. 2026, 20:40 UTC

Acquisitions, Fusions, Rachats

Blackstone Investment Positions Rowan to Continue Delivering Sustainable Data Center Capacity for World's Leading Technology Cos >BX

9 avr. 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Blackstone Blackstone Acquired Significant Minority Stake in Rowan Digital Infrastructure >BX

9 avr. 2026, 20:39 UTC

Acquisitions, Fusions, Rachats

Rowan Digital Infrastructure Announces Strategic Recapitalization

9 avr. 2026, 20:25 UTC

Acquisitions, Fusions, Rachats

SBA Communications Stock Soars on Buyout Interest. What It Means for Tower Stocks. -- Barrons.com

9 avr. 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 avr. 2026, 19:30 UTC

Principaux Événements d'Actualité

How Digital Currencies Have Helped Iran -- WSJ

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

56.65% hausse

Prévisions sur 12 Mois

Moyen 37 USD  56.65%

Haut 46 USD

Bas 32 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

4

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

154 / 348Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat